This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
by Zacks Equity Research
AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.
AZNNegative Net Change PRTANegative Net Change AGENNegative Net Change AKRONegative Net Change
biotechs medical pharmaceuticals
MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights
by Zacks Equity Research
Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity through 2044.
BAYRYNegative Net Change AGENNegative Net Change MDGLNegative Net Change VRNAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock
by Ahan Chakraborty
RXRX gains 5.5% in a month on positive pipeline update; long-term hold advised given strong potential of its AI-driven drug discovery platform.
SNYNegative Net Change RHHBYNegative Net Change BAYRYNegative Net Change RXRXNegative Net Change
artificial-intelligence biotechnology biotechs medical oncology-screening pharmaceuticals
Mirum Gains 35% in 3 Months: How Should You Play the Stock?
by Zacks Equity Research
MIRM jumps 35% in 3 months, driven by soaring Livmarli sales and rising demand for its bile acid products.
ARVNNegative Net Change AKRONegative Net Change MIRMNegative Net Change
biotechs
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
by Ahan Chakraborty
RXRX is scaling its AI-driven drug discovery technology through billion-dollar pharma deals and strategic tech alliances.
SDGRNegative Net Change RLAYNegative Net Change RXRXNegative Net Change
artificial-intelligence biotechnology biotechs medical pharmaceuticals
Will Increased Expenses Affect Bristol Myers' Performance?
by Ekta Bagri
BMY inks $3.5B bispecific antibody deal with BioNTech as top-line pressures and bottom-line risks mount.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?
by Sundeep Ganoria
ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.
AZNNegative Net Change PFENegative Net Change MRKNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention
by Zacks Equity Research
MRK launches Phase III trials for its once-monthly HIV prevention pill MK-8527, aiming to rival Gilead's daily PrEP options.
GSKNegative Net Change MRKNegative Net Change GILDNegative Net Change
biotechs medical pharmaceuticals
How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?
by Sundeep Ganoria
PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.
AZNNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechs earnings medical pharmaceuticals
Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
AstraZeneca Meets All Key Goals in Phase III Hypertension Study
by Zacks Equity Research
AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.
AZNNegative Net Change BAYRYNegative Net Change AGENNegative Net Change VRNAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA
by Zacks Equity Research
RARE faces regulatory setback as FDA issues a CRL for UX111, delaying approval of the MPS IIIA gene therapy until 2026.
BAYRYNegative Net Change AGENNegative Net Change RARENegative Net Change VRNAPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks
by Zacks Equity Research
Capricor slumps 33% as the FDA rejects its BLA for DMD drug, deramiocel, citing lack of effectiveness data and CMC issues.
ALKSNegative Net Change CAPRNegative Net Change BTAINegative Net Change ARVNNegative Net Change
biotechs
FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults
by Zacks Equity Research
FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.
GSKNegative Net Change PFENegative Net Change MRNANegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Bayer Gets FDA Nod for Label Expansion of Kerendia in Heart Failure
by Zacks Equity Research
BAYRY wins FDA nod to expand Kerendia's label, making it the only approved non-steroidal MR antagonist for two major conditions.
NVSNegative Net Change JNJNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
MRNA Stock Up on Full FDA Nod for COVID-19 Jab in Pediatric Patients
by Zacks Equity Research
Moderna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to 11 years.
PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change
biotechs
MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success
by Zacks Equity Research
Merus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.
MRKNegative Net Change BAYRYNegative Net Change MRUSNegative Net Change VRNAPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Bayer Wins Hormone-Free Treatment Approval for Women in the UK
by Zacks Equity Research
BAYRY secures first global approval for Lynkuet in the UK, a hormone-free treatment for menopause-related hot flashes.
NVSNegative Net Change JNJNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?
by Ekta Bagri
AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.
BMYNegative Net Change ABBVNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?
by Sundeep Ganoria
LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up
by Zacks Equity Research
Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.
ALKSNegative Net Change AMRNPositive Net Change KRYSNegative Net Change KROSNegative Net Change
biotechs
RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data
by Zacks Equity Research
Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.
ALKSNegative Net Change AMRNPositive Net Change RYTMNegative Net Change KROSNegative Net Change
biotechs
RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End
by Zacks Equity Research
Ultragenyx Pharmaceutical and Mereo BioPharma shares tumble as investors await key phase III UX143 osteogenesis data now set for release at year-end.
BAYRYNegative Net Change RARENegative Net Change VRNAPositive Net Change MREOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Pharma Companies Remain Calm Amid Fresh Tariff Threat by Trump
by Ekta Bagri
Trump revives tariff threats on pharma imports, but industry giants like LLY and JNJ stay unfazed with major U.S. investments underway.
NVSNegative Net Change RHHBYNegative Net Change JNJNegative Net Change LLYNegative Net Change
biotechnology biotechs medical pharmaceuticals
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?
by Zacks Equity Research
KalVista jumps 36% in a week after the FDA clears Ekterly, the first oral on-demand therapy for hereditary angioedema.
AGENNegative Net Change AMRNPositive Net Change KALVNegative Net Change TAKNegative Net Change
biotechs medical